Iuliano R, Pizzigallo A M, Alecci A, Barsanti L, Trovato R, Forastieri G, Lico S, Palmieri C, Brizzi M, Marino N, Mecocci L, Mazzotta F, Ceccherini-Nelli L
Dept. of Biomedicine, University of Pisa, Italy.
Infection. 1996 Jul-Aug;24(4):292-6. doi: 10.1007/BF01743362.
Using bDNA, the plasma viral load trend of HCV-infected patients undergoing IFN therapy was analyzed. Nine patients were enrolled, each assigned to one of three groups, based on IFN response as determined by ALT and AST level trend. HCV was genotyped using DEIA. Each patient's clinical stage was determined by liver biopsy analysis. In nonresponding patients elevated viral loads and biochemical parameters were observed. These values were not influenced by IFN treatment. In relapsed patients the cessation of IFN treatment increased viral load; this was associated with a rise in ALT and AST values. In responders ALT and AST levels remained normal; viral load was low. Patients with elevated HCV viral load showed a worsening in their liver histology during the follow-up period. These results confirm that plasma viral load is a good marker of biochemical change and disease progression.
采用分支DNA技术分析了接受干扰素治疗的丙型肝炎病毒(HCV)感染患者的血浆病毒载量变化趋势。招募了9名患者,根据谷丙转氨酶(ALT)和谷草转氨酶(AST)水平变化趋势所确定的干扰素反应,将每位患者分配到三个组中的一组。使用核酸分子杂交技术对HCV进行基因分型。通过肝活检分析确定每位患者的临床分期。在无反应患者中观察到病毒载量和生化指标升高。这些值不受干扰素治疗的影响。在复发患者中,停止干扰素治疗会导致病毒载量增加;这与ALT和AST值升高有关。在有反应的患者中,ALT和AST水平保持正常;病毒载量较低。HCV病毒载量升高的患者在随访期间肝脏组织学出现恶化。这些结果证实血浆病毒载量是生化变化和疾病进展的良好标志物。